Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost SR versus selective laser trabeculoplasty in open-angle glaucoma or ocular hypertension
MOH_2017-04-05_000280Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by AbbVie Inc. Started May 2016; status: recruiting.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on MOH_2017-04-05_000280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-05_000280.